|
|
Article: Glaxo Wellcome Inc. Receives Clearance to Market Imitrex(R) Nasal Spray in the U.S.
- Article from:
- PR Newswire
- Article date:
- September 2, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., Sept. 2 /PRNewswire/ -- Glaxo Wellcome Inc. (NYSE: GLX) has received clearance from the United States Food and Drug Administration to market the nasal spray form of Imitrex(R) (sumatriptan). Imitrex is the company's innovative therapy for the acute treatment of migraine and is currently available in the U.S. in subcutaneous injection form and tablet form.
Imitrex Nasal Spray will expand the family of Imitrex products to provide a wide range of treatment options for people who suffer from migraine and want effective, nonsedating relief. This new formulation will offer an alternative for those using oral medications who are ...